Paving the way for future PSMA inhibitors: insights from comparative preclinical evaluations of structure modifications

Abstract Background Prostate-specific membrane antigen (PSMA) is an established target for the imaging and treatment of prostate cancer. This study focused on the preclinical evaluation of three novel PSMA inhibitors—P15, P16, and P19—which were structurally modified compared to the clinically used...

Full description

Bibliographic Details
Published in:	EJNMMI Radiopharmacy and Chemistry
Main Authors:	Katarína Hajduová, Kateřina Dvořáková Bendová, Miloš Petřík, Martina Benešová-Schäfer, Martin Schäfer, Marián Hajdúch, Zbyněk Nový
Format:	Article
Language:	English
Published:	SpringerOpen 2025-09-01
Subjects:	PSMA Prostate cancer Preclicnical PET/CT Theranostics Radiopharmaceuticals
Online Access:	https://doi.org/10.1186/s41181-025-00389-w

Similar Items

Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System
by: Zsófia Sára Mikó, et al.
Published: (2024-10-01)

Current status of PSMA-targeted imaging and therapy
by: Hui Wang, et al.
Published: (2024-01-01)

COMPARISON OF PET/CT IMAGES WITH 18F-FDG AND 18F-PSMA-1007 IN MUSCULOSKELETAL TUMORS TO EVALUATE THE POTENTIAL OF THERANOSTICS APPROACH
by: Mayara Branco E. Silva, et al.
Published: (2024-04-01)

Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer
by: Jan Heilinger, et al.
Published: (2023-09-01)

COMPARISON OF 18F-FDG AND 18F-PSMA PET/CT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
by: Najua Abou Arabi Silveira, et al.
Published: (2024-04-01)

Current State of Evidence and Practice of Prostate-Specific Membrane Antigen (Psma) Imaging Across the Prostate Cancer Clinical Landscape – Oncologist Perspective
by: Antonela Njavro, et al.
Published: (2024-01-01)

The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
by: Atefeh Zamanian, et al.
Published: (2025-07-01)

FDG PET/CT AND PSMA PET/CT IN MUSCULOSKELETAL SOFT TISSUE SARCOMAS
by: Ellen Nogueira Lima, et al.
Published: (2025-05-01)

Ga-68 PSMA PET/CT: Enhancing diagnostic precision and clinical decision-making in prostate cancer
by: Fatih Bati
Published: (2025-04-01)

COMPETITION RESPONSE OF PSMA-I&T RADIOLABELED WITH LUTETIUM-177 TO LNCAP, PC-3 AND RWPE-1 CELLS
by: Luiza M Balieiro, et al.
Published: (2025-05-01)

Optimized <sup>68</sup>Ga-Labeled Urea-Based PSMA-Targeted PET Tracers for Prostate Cancer
by: Yitian Wu, et al.
Published: (2022-08-01)

APPLICABILITY OF PSMA PET/CT IN THE EVALUATION OF ADENOID CYSTIC CARCINOMA
by: Lucas Pinho, et al.
Published: (2025-05-01)

Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
by: Mathieu Gaudreault, et al.
Published: (2023-03-01)

177Lu-PSMA radioligand therapy for isolated bilateral adrenal metastases from prostate cancer
by: Elisabetta Perrone, et al.
Published: (2024-07-01)

Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation
by: Lesniak WG, et al.
Published: (2024-05-01)

Radiosynthesis and Preclinical Evaluation of Bispecific PSMA/FAP Heterodimers for Tumor Imaging
by: Kongzhen Hu, et al.
Published: (2022-03-01)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
by: Ayman Abouzayed, et al.
Published: (2019-07-01)

Advances in PSMA theranostics
by: Thomas M. Jeitner, et al.
Published: (2022-08-01)

Comment on “PSMA response evaluation in follow-up PSMA-PET/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer”
by: Parth Aphale, et al.
Published: (2025-11-01)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
by: Suzanne van der Gaag, et al.
Published: (2022-11-01)

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
by: Nat P. Lenzo, et al.
Published: (2018-02-01)

Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
by: Louise Emmett, et al.
Published: (2017-03-01)

TREATMENT OF REFRACTORY MULTIPLE MYELOMA WITH PSMA-177LU: A CASE REPORT
by: Kaique M. Amaral, et al.
Published: (2024-04-01)

[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2021-07-01)

Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents
by: Ute Hennrich, et al.
Published: (2025-06-01)

Beyond Small Molecules: Antibodies and Peptides for Fibroblast Activation Protein Targeting Radiopharmaceuticals
by: Xiaona Sun, et al.
Published: (2024-02-01)

A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer
by: Ann-Christin Eder, et al.
Published: (2022-02-01)

PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches
by: Vinh Ngoc Bui, et al.
Published: (2023-11-01)

Radioactive gold nanocluster (198-AuNCs) showed inhibitory effects on cancer cells lines
by: Shijin Xuan, et al.
Published: (2020-01-01)

Estimation of relative biological effectiveness of 225Ac compared to 177Lu during [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
by: Mikhail Rumiantcev, et al.
Published: (2023-09-01)

<sup>64</sup>Cu-DOTHA<sub>2</sub>-PSMA, a Novel PSMA PET Radiotracer for Prostate Cancer with a Long Imaging Time Window
by: Marie-Christine Milot, et al.
Published: (2022-08-01)

Incidental Finding of a PSMA-Positive Pancreatic Cancer in a Patient Suffering from a Metastasized PSMA-Positive Prostate Cancer
by: Simon Sirtl, et al.
Published: (2021-01-01)

Preclinical characterisation of gallium-68 labeled ferrichrome siderophore stereoisomers for PET imaging applications
by: Kristyna Krasulova, et al.
Published: (2024-03-01)

Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study
by: Seyed Ali Mirshahvalad, et al.
Published: (2023-01-01)

An HPLC and UHPLC-HRMS approach to study PSMA-11 instability in aqueous solution
by: Antonella Iudicello, et al.
Published: (2021-03-01)

Stability in the production and transport of 177Lu labelled PSMA
by: Cristian Antonio Wieczorek Villas Boas, et al.
Published: (2021-03-01)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
by: Kevin H. Leung, et al.
Published: (2022-12-01)

Evaluation of genotoxic potential of peptides used in nuclear medicine (PSMA -617 and -11, and ubiquicidine 29-41) using a flow-cytometric, semi-automated analysis of micronuclei frequency in cell cultures
by: L.R. de Carvalho, et al.
Published: (2020-01-01)

Early treatment response assessment with [177Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET
by: David Ventura, et al.
Published: (2024-09-01)

Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617 Uptake?
by: Harun Taş, et al.
Published: (2024-04-01)